Last reviewed · How we verify
NCT03293641
Zinc Supplementation in Children With Sickle Cell Disease in Western Kenya
NA trial testing Zinc Sulfate Tablets in Sickle Cell Disease in 40 participants. Completed in 19 January 2017.
19 January 2017
Quick facts
| Lead sponsor | Lucas Otieno Tina, MD MSc |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 40 |
| Start date | 20 May 2016 |
| Primary completion | 19 January 2017 |
| Estimated completion | 19 January 2017 |
Drugs / interventions tested
- Zinc Sulfate Tablets
- Standard of Care
Conditions studied
- Sickle Cell Disease — all drugs for Sickle Cell Disease →
- Zinc Deficiency — all drugs for Zinc Deficiency →
- Infection — all drugs for Infection →
Sponsor
Lucas Otieno Tina, MD MSc
Who can join
Adults 6 Months to 12, any sex, with Sickle Cell Disease or Zinc Deficiency. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Zinc is a nutritionally essential trace element found in previous studies to reduce growth retardation and improve immune function, which may also result in decreased incidence of infectious diseases including malaria, pneumonia and diarrhea. Sickle Cell Disease (SCD) patients are known to be susceptible to zinc deficiency and appear to benefit from zinc supplementation. The proposed pilot research project aims to investigate the influence of zinc supplementation on incidence of malaria infections, incidence of bacterial infections and investigate the influence of zinc supplementation on morbidity in children with SCD in western Kenya. The differences in incidence of morbidity and other secondary endpoints will be compared between the zinc group and the control group.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Antioxidant supplementation for sickle cell disease.
Bolarinwa AB, Oduwole O, Okebe J, Ogbenna AA, et al · · 2024 · cited 3× · PMID 38775255 · DOI 10.1002/14651858.cd013590.pub2
Verify or expand the search:
- PubMed search for NCT03293641
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Sickle Cell Disease
Currently open trials in the same condition.
- NCT07369024 — Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults · Phase 2 · recruiting
- NCT06016634 — Alendronate for Osteonecrosis in Adults With Sickle Cell Disease · Phase 2 · recruiting
- NCT06260891 — Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial · Phase 2 · recruiting
- NCT07222475 — Writing Relaxing Beats in Adolescents Who Have Sickle Cell Disease · NA · recruiting
- NCT07224360 — Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD) · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03293641 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Lucas Otieno Tina, MD MSc
- Last refreshed: 26 September 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03293641.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing